Blockchain Registration Transaction Record
Danish Biotech Lophora Initiates Phase 1 Trial of Novel Compound LPH-5 for CNS Disorders
Lophora, a Danish biotech, starts Phase 1 trial of novel compound LPH-5 targeting CNS disorders. With potential therapeutic benefits and non-hallucinogenic effects, this development could transform the treatment of neurological and psychiatric conditions.
This news highlights a significant milestone in the development of next-generation psychedelic therapies for CNS disorders. The advancement of LPH-5 by Lophora could potentially revolutionize the treatment landscape for conditions like depression and anxiety, offering hope for patients with treatment-resistant forms of these disorders.
| Blockchain | Details |
|---|---|
| Contract Address | 0xeA2912a8DA1CD48401b10cB283585874d98098F4 |
| Transaction ID | 0x034f0287171ef93ebc454bafe05df4aae7d3c59379e10aa00e13104cd5b4a73a |
| Account | 0xdBdE7c76e403a5923F3dD4F050Dbbf5c2077BB20 |
| Chain | polygon-main |
| NewsRamp Digital Fingerprint | plumbKNI-944fe92ad8ff66ca7108cbd1406af95e |